Leukemia, Chronic Lymphocytic disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

CLL MCID: LKM071 MIFTS: 75	Leukemia, Chronic Lymphocytic (CLL) Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Leukemia, Chronic Lymphocytic

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic:

Name: Leukemia, Chronic Lymphocytic ⁵⁷ ⁷³ ³⁶ ³⁸

Chronic Lymphocytic Leukemia ¹¹ ¹⁹ ⁷⁵ ⁴¹ ¹⁴ ¹⁶ ⁷¹

B-Cell Chronic Lymphocytic Leukemia ¹¹ ⁵⁸ ⁷³ ²⁸ ⁵

Cll ⁵⁷ ¹¹ ⁷³

B-Cell Chronic Lymphoid Leukemia ¹¹ ⁵⁸

Chronic Lymphocytic Leukaemia ¹¹ ¹⁴

Chronic Lymphatic Leukemia ¹¹ ⁷³

Lymphoplasmacytic Leukemia ¹¹ ⁷¹

Small Lymphocytic Lymphoma ⁵⁸ ⁷¹

Leukemia, Lymphocytic, Chronic, B-Cell ⁴³

B-Cell Chronic Lymphocytic Leukaemia ¹¹

B Cell Chronic Lymphocytic Leukemia ¹⁹

Chronic B-Cell Lymphocytic Leukemia ¹⁹

Leukemia, Lymphocytic, Chronic ¹⁹

Leukemia Lymphocytic Chronic ⁵³

Leukemia, Chronic Lymphatic ⁵⁷

Chronic Lymphatic Leukaemia ¹¹

Lymphoplasmacytic Leukaemia ¹¹

Lymphoma Small Lymphocytic ⁵³

Chronic Lymphoid Leukemia ⁷³

B-Cll ⁵⁸

Characteristics:

Inheritance:

Leukemia, Chronic Lymphocytic: Autosomal dominant ⁵⁷

B-Cell Chronic Lymphocytic Leukemia: Multigenic/multifactorial ⁵⁸

Prevelance:

B-Cell Chronic Lymphocytic Leukemia: 1-5/10000 (Europe) 1-9/100000 (France) ⁵⁸

Age Of Onset:

B-Cell Chronic Lymphocytic Leukemia: Adult ⁵⁸

OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Miscellaneous:
associated with susceptibility loci on chromosome 11p11 (clls1, ), 13q14 (clls2, ), 9q34.1 (clls3, ), 6p25.3 (clls4, ), and 11q24.1 (clls5, )

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Lymphoid leukaemia

Chronic lymphocytic leukaemia of B-cell type

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:1040

OMIM® ⁵⁷ 151400

ICD9CM ³⁴ 204.1

MeSH ⁴³ D015451

NCIt ⁴⁹ C3163

SNOMED-CT ⁶⁸ 51092000

MESH via Orphanet ⁴⁴ D015451

ICD10 via Orphanet ³² C91.1

UMLS via Orphanet ⁷² C0023434 C0855095 C1868683

Orphanet ⁵⁸ ORPHA67038

MedGen ⁴⁰ C0023434

SNOMED-CT via HPO ⁶⁹ 277473004 92814006

EFO ¹⁶ EFO_0000095

UMLS ⁷¹ C0023434 C0855095 C2854089

Sources

Summaries for Leukemia, Chronic Lymphocytic

MedlinePlus: ⁴¹ What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What is chronic lymphocytic leukemia (CLL)? Chronic lymphocytic leukemia (CLL) is a type of chronic leukemia. "Chronic" means that the leukemia usually gets worse slowly. In CLL, the bone marrow makes abnormal lymphocytes (a type of white blood cell). When the abnormal cells crowd out the healthy cells, it can lead to infection, anemia, and easy bleeding. The abnormal cells can also spread outside the blood to other parts of the body. CLL is one of the most common types of leukemia in adults. It often occurs during or after middle age. It is rare in children. What causes chronic lymphocytic leukemia (CLL)? CLL happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown, so it's hard to predict who might get CLL. There are a few factors that might raise your risk. Who is at risk for chronic lymphocytic leukemia (CLL)? It is hard to predict who will get CLL. There are a few factors that could raise your risk: Age - your risk goes up as you get older. Most people who are diagnosed with CLL are over 50. Family history of CLL and other blood and bone marrow diseases Racial/ethnic group - CLL is more common in whites than in people from other racial or ethnic groups Exposure to certain chemicals, including Agent Orange, a chemical that was used in the Vietnam War What are the symptoms of chronic lymphocytic leukemia (CLL)? In the beginning, CLL does not cause any symptoms. Later, you can have symptoms such as: Swollen lymph nodes - you may notice them as painless lumps in the neck, underarm, stomach, or groin Weakness or feeling tired Pain or a feeling of fullness below the ribs Fever and infection Easy bruising or bleeding Petechiae, which are tiny red dots under the skin. They are caused by bleeding. Weight loss for no known reason Drenching night sweats How is chronic lymphocytic leukemia (CLL) diagnosed? Your health care provider may use many tools to diagnose CLL: A physical exam A medical history Blood tests, such as a complete blood count (CBC) with differential and blood chemistry tests. Blood chemistry tests measure different substances in the blood, including electrolytes, fats, proteins, glucose (sugar), and enzymes. Specific blood chemistry tests include a basic metabolic panel (BMP), a comprehensive metabolic panel (CMP), kidney function tests, liver function tests, and an electrolyte panel. Flow cytometry tests, which check for leukemia cells and identify which type of leukemia it is. The tests can be done on blood, bone marrow, or other tissue. Genetic tests to look for gene and chromosome changes If you are diagnosed with CLL, you may have additional tests to see whether the cancer has spread. These include imaging tests and bone marrow tests. What are the treatments for chronic lymphocytic leukemia (CLL)? Treatments for CLL include: Watchful waiting, which means that you don't get treatment right away. Your health care provider regularly checks to see if your signs or symptoms appear or change. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Chemotherapy Radiation therapy Immunotherapy Chemotherapy with bone marrow or stem cell transplant The goals of treatment are to slow the growth of the leukemia cells and to give you long periods of remission. Remission means that the signs and symptoms of cancer are reduced or have disappeared. The CLL may come back after remission, and you may need more treatment. NIH: National Cancer Institute

MalaCards based summary: Leukemia, Chronic Lymphocytic, also known as chronic lymphocytic leukemia, is related to richter's syndrome and chronic lymphocytic leukemia/small lymphocytic lymphoma, and has symptoms including fatigue, angina pectoris and chest pain. An important gene associated with Leukemia, Chronic Lymphocytic is TP53 (Tumor Protein P53), and among its related pathways/superpathways are miRNA regulation of DNA damage response and DNA damage response (only ATM dependent). The drugs Ofatumumab and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are cellular immunodeficiency and chronic lymphatic leukemia

Orphanet: ⁵⁸ B-cell chronic lymphocytic leukemia (B-CLL) is a type of B-cell non-Hodgkin lymphoma (see this term), and the most common form of leukemia in Western countries, affecting elderly adults (mean age of 67 and 72 years) with a slight male predominance (1.7:1), and characterized by a highly variable clinical presentation that can include asymptomatic disease or non-specific B-symptoms such as unintentional weight loss, severe fatigue, fever (without evidence of infection), and night sweats as well as cervical lymphadenopathy, splenomegaly and frequent infections. Some patients can also develop autoimmune complications such as autoimmune hemolytic anemia or immune thrombocytopenia (see these terms). The clinical course is extremely heterogeneous with survival ranging from a few months to several decades.

GARD: ¹⁹ Chronic lymphocytic leukemia (CLL) is a type of cancer of the white blood cells (lymphocytes). Early signs and symptoms may include swollen lymph nodes, fatigue, weight loss, fever, night sweats and/or frequent infections. Over time, CLL may also spread to the lymph nodes and other organs, including the liver, spleen and lungs. The underlying cause is thought to be a combination of genetic and other unknown factors. It usually occurs in people with no family history of the condition, but familial cases have been reported. CLL is diagnosed based on the symptoms and various blood tests.

OMIM®: ⁵⁷ Chronic lymphocytic leukemia (CLL) is a common neoplasia of B lymphocytes in which these cells progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival (summary by Quesada et al., 2012). (151400) (Updated 08-Dec-2022)

UniProtKB/Swiss-Prot: ⁷³ A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.

Disease Ontology: ¹¹ A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.

Wikipedia: ⁷⁵ Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many... more...

Sources

Related Diseases for Leukemia, Chronic Lymphocytic

Diseases in the Leukemia, Chronic Lymphocytic family:

Leukemia, Chronic Lymphocytic 2	Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 3	Leukemia, Chronic Lymphocytic 4
Leukemia, Chronic Lymphocytic 5	Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1342)

#	Related Disease	Score	Top Affiliating Genes
1	richter's syndrome	33.1	TP53 RPS15 ATM
2	chronic lymphocytic leukemia/small lymphocytic lymphoma	32.9	TP53 MIR15A CCND1
3	lung cancer	32.4	TP53COR1 TP53 NEAT1 MIR424 MIR34A MIR29A
4	burkitt lymphoma	32.4	TP53COR1 TP53 NEAT1 MIR29A MIR145 MIR143
5	melanoma	32.2	TP53 POT1 MIR34A MIR181A2 MIR15A MIR107
6	lymphoma, non-hodgkin, familial	32.1	TP53 MIR424 MIR34A MIR15A MIR145 MIR143
7	renal cell carcinoma, nonpapillary	32.1	TP53 MIR424 MIR34A MIR15A MIR145 MIR143
8	peripheral nervous system disease	32.0	TP53 MIR34A MIR29A MIR145 MIR143 CCND1
9	leukemia, acute myeloid	31.9	TP53 MIR424 MIR34A MIR29A MIR181A2 MIR145
10	connective tissue disease	31.9	TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
11	esophageal cancer	31.8	TP53 MIR424 MIR34A MIR29A MIR145 MIR143
12	mantle cell lymphoma	31.8	TP53 MIR16-1 IKZF3 CCND1 ATM
13	lymphatic system disease	31.8	TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
14	cervical cancer	31.7	TP53COR1 TP53 NEAT1 MIR424 MIR34A MIR16-1
15	diffuse large b-cell lymphoma	31.7	MIR15A MIR145 MIR143 MIR106B
16	prostate cancer	31.6	TP53COR1 TP53 NEAT1 MIR34A MIR29A MIR16-1
17	kidney cancer	31.6	TP53 MIR424 MIR29A MIR15A MIR145 MIR106B
18	myeloma, multiple	31.6	TP53 MIR181A2 MIR15A MIR145 MIR106B CCND1
19	nervous system disease	31.6	TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
20	chromosome 13q14 deletion syndrome	31.5	TP53 MIR15A ATM
21	prolymphocytic leukemia	31.5	TP53 CCND1 ATM
22	gastric cancer	31.5	TP53COR1 TP53 NEAT1 MIR34A MIR16-1 MIR15A
23	ovarian cancer	31.5	TP53 NEAT1 MIR424 MIR34A MIR29A MIR145
24	hepatocellular carcinoma	31.5	TP53COR1 TP53 NEAT1 MIR424 MIR34A MIR29A
25	colorectal cancer	31.5	TP53COR1 TP53 NEAT1 MIR424 MIR34A MIR29A
26	rectum cancer	31.4	TP53 MIR424 MIR29A MIR145 MIR143
27	hematologic cancer	31.4	MIR424 MIR34A MIR29A MIR16-1 MIR15A MIR145
28	larynx cancer	31.4	TP53 MIR145 MIR143 MIR106B CCND1
29	colonic benign neoplasm	31.4	TP53 MIR15A MIR145 MIR143 CCND1 ATM
30	central nervous system disease	31.4	MIR34A MIR29A MIR15A MIR145 MIR143 MIR106B
31	brain cancer	31.4	TP53 MIR34A MIR145 MIR143 MIR106B
32	gastrointestinal system disease	31.3	MIR424 MIR34A MIR29A MIR15A MIR145 MIR143
33	laryngeal benign neoplasm	31.3	TP53 MIR106B CCND1
34	oral squamous cell carcinoma	31.2	NEAT1 MIR424 MIR34A MIR29A MIR145 MIR143
35	rectal benign neoplasm	31.2	TP53 MIR145 MIR143
36	gallbladder disease	31.2	TP53 MIR145 MIR143 CCND1
37	central nervous system cancer	31.2	TP53 MIR34A MIR15A MIR145 MIR143 MIR106B
38	colorectal adenocarcinoma	31.2	TP53 MIR29A MIR145 MIR143 CCND1
39	glioma	31.1	TP53COR1 TP53 NEAT1 MIR34A MIR181A2 MIR15A
40	type 2 diabetes mellitus	31.0	TP53 MIR34A MIR29A MIR145 MIR143 MIR106B
41	esophagus adenocarcinoma	31.0	TP53 MIR145 MIR143 CCND1
42	nasopharyngeal carcinoma	31.0	TP53 NEAT1 MIR145 MIR143 CCND1
43	bone marrow cancer	31.0	TP53 MIR34A MIR145 CCND1
44	melanoma, cutaneous malignant 1	31.0	TP53 POT1 CCND1 ATM
45	tongue carcinoma	30.9	TP53 MIR15A MIR143 CCND1
46	squamous cell carcinoma, head and neck	30.9	TP53 MIR424 MIR15A MIR145 MIR143 MIR106B
47	dyskeratosis congenita	30.9	TP53 RPS15 POT1 ATM
48	endometriosis	30.9	TP53 MIR424 MIR145 MIR143
49	lung cancer susceptibility 3	30.8	TP53 MIR15A MIR145 MIR143 MIR106B CCND1
50	high grade glioma	30.7	TP53COR1 TP53 NEAT1 MIR145 ATM

Comorbidity relations with Leukemia, Chronic Lymphocytic via Phenotypic Disease Network (PDN): (show all 12)

Acquired Thrombocytopenia	Acute Cystitis
Agammaglobulinemia, X-Linked	Anemia, Autoimmune Hemolytic
Bronchitis	Chronic Leukemia
Deficiency Anemia	Familial Atrial Fibrillation
Heart Disease	Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Leukemia	Neutropenia

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic:

Sources

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic

Human phenotypes related to Leukemia, Chronic Lymphocytic:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	cellular immunodeficiency ³⁰			HP:0005374
2	chronic lymphatic leukemia ³⁰			HP:0005550

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Hematology:
chronic lymphatic leukemia

Laboratory Abnormalities:
recurring t(11,14) and t(14,19)(q32,q13.1) translocations

Immunology:
impaired cellular and humoral immunity

Clinical features from OMIM®:

151400 (Updated 08-Dec-2022)

UMLS symptoms related to Leukemia, Chronic Lymphocytic:

fatigue; angina pectoris; chest pain; edema

Sources

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic

Drugs for Leukemia, Chronic Lymphocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 453)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ofatumumab

Approved

Phase 4

679818-59-8

Valganciclovir

Approved, Investigational

Phase 4

175865-60-8

64147

Acalabrutinib

Approved, Investigational

Phase 4

1420477-60-6

71226663 71226662

Chlorambucil

Approved

Phase 4

305-03-3

2708

Epoetin Alfa

Phase 4

Hematinics

Phase 4

Chrysarobin

Phase 4

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

4112 126941

Cytarabine

Approved, Investigational

Phase 3

147-94-4

6253

Arsenic trioxide

Approved, Investigational

Phase 3

1327-53-3

518740

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Darbepoetin alfa

Approved, Investigational

Phase 3

209810-58-2

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Vidarabine

Approved, Investigational

Phase 3

24356-66-9

21704

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Venetoclax

Approved, Investigational

Phase 3

1257044-40-8

49846579

Obinutuzumab

Approved, Investigational

Phase 3

949142-50-1

Triamcinolone

Approved, Vet_approved

Phase 3

124-94-7

31307

Pancrelipase

Approved, Investigational

Phase 3

53608-75-6

8519

Fludarabine

Approved

Phase 2, Phase 3

75607-67-9, 21679-14-1

30751 657237

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Mitoxantrone

Approved, Investigational

Phase 3

70476-82-3, 65271-80-9

4212

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 3

67-97-0, 1406-16-2

5280795 10883523

Antimetabolites

Phase 3

Antiviral Agents

Phase 3

Anti-Infective Agents

Phase 3

Dermatologic Agents

Phase 3

Anti-Bacterial Agents

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Antibiotics, Antitubercular

Phase 3

Liposomal doxorubicin

Phase 3

Cyclosporins

Phase 3

Antifungal Agents

Phase 3

Ferric Oxide, Saccharated

Phase 3

Folic Acid Antagonists

Phase 3

Folate

Phase 3

Vitamin B9

Phase 3

Vitamin B Complex

Phase 3

Caseins

Phase 2, Phase 3

Triamcinolone hexacetonide

Phase 3

Triamcinolone diacetate

Phase 3

Triamcinolone Acetonide

Phase 3

6436

Liver Extracts

Phase 3

Immunoglobulin G

Phase 3

Paraproteins

Phase 3

Interventional clinical trials:

(show top 50) (show all 1467)

#	Name	Status	NCT ID	Phase	Drugs
1	A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia.	Unknown status	NCT00131313	Phase 4	Nipent, Cytoxan, Rituxan
2	The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia	Completed	NCT00524407	Phase 4	Epoetin alfa
3	A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia	Completed	NCT01056510	Phase 4	bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
4	A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia	Completed	NCT00220311	Phase 4	Fludarabine Phosphate (Fludara)
5	Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study	Completed	NCT01255644	Phase 4	Valganciclovir
6	The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL	Completed	NCT00919321	Phase 4
7	A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406	Completed	NCT00802737	Phase 4	Ofatumumab
8	A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion	Active, not recruiting	NCT03190330	Phase 4	Ibrutinib 420 mg;Ibrutinib 560 mg
9	Long Term Effect on Immune Response After Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukemia and Evaluation of the Effect of Revaccination	Active, not recruiting	NCT05316831	Phase 4
10	A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma	Active, not recruiting	NCT04930536	Phase 4	Acalabrutinib capsule
11	Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens	Not yet recruiting	NCT04790045	Phase 4	Venetoclax
12	Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment	Terminated	NCT02608060	Phase 4	Epoetin Beta
13	Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status	Terminated	NCT01283386	Phase 4	Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
14	Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status	Terminated	NCT01271010	Phase 4	Cyclophosphamide;Fludarabine;Rituximab
15	Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers	Unknown status	NCT02991638	Phase 3	Ibrutinib
16	Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3)	Unknown status	NCT00017108	Phase 3	chlorambucil;cyclophosphamide;fludarabine phosphate
17	Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia	Unknown status	NCT01670812	Phase 3	FFP+HDMP+Rituximab
18	Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients	Unknown status	NCT01657955	Phase 3	Bendamustine Hydrochloride Injection;Chlorambucil
19	A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia	Unknown status	NCT02186574	Phase 3	Tenofovir disoproxil;Placebo Oral Tablet
20	A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL	Unknown status	NCT02475681	Phase 3	Acalabrutinib;Obinutuzumab;Chlorambucil
21	A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL	Unknown status	NCT01678430	Phase 3	Ofatumumab;Chlorambucil;Bendamustine
22	Combination of Ibrutinib and As2O3 in the Treatment of CLL	Unknown status	NCT02757040	Phase 3	Ibrutinib combined with As2O3;ibrutinib
23	Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial	Unknown status	NCT01516580	Phase 3	Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
24	A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial	Completed	NCT01231412	Phase 3	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
25	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
26	A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia	Completed	NCT01892618	Phase 3	Prevenar 13;Pneumovax
27	A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07	Completed	NCT02049515	Phase 3	IPI-145 (duvelisib);Ofatumumab
28	Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO	Completed	NCT00645606	Phase 3
29	Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)	Completed	NCT02756611	Phase 3	Venetoclax
30	A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia	Completed	NCT00824265	Phase 3	OFC Infusion;FC infusion
31	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)	Completed	NCT00774345	Phase 3	Lenalidomide;Placebo
32	A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)	Completed	NCT02301156	Phase 3	Ublituximab;Ibrutinib
33	A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity	Completed	NCT03730129	Phase 2, Phase 3	Hizentra
34	A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia	Completed	NCT01905943	Phase 3	Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab
35	A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab	Completed	NCT02005471	Phase 3	Bendamustine;Venetoclax;Rituximab
36	Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)	Completed	NCT02980731	Phase 3	Venetoclax
37	A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Completed	NCT01973387	Phase 3	Rituximab;Ibrutinib
38	A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Completed	NCT02264574	Phase 3	Ibrutinib;Obinutuzumab;Chlorambucil
39	A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With Mabthera (Rituximab) Versus No Treatment, After Induction Treatment With Rituximab, Cladribine and Cyclophosphamide (RCC) on Progression-Free Survival in Previously Untreated Patients With Progressive B-Cell Chronic Lymphocytic Leukemia	Completed	NCT00718549	Phase 3	Cladribine;Cyclophosphamide;Rituximab
40	A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)	Completed	NCT02004522	Phase 3	Duvelisib;Ofatumumab
41	Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia	Completed	NCT00024440	Phase 3	cyclophosphamide;fludarabine phosphate
42	Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Completed	NCT01611090	Phase 3	Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
43	A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia	Completed	NCT00086580	Phase 3
44	A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial)	Completed	NCT00910910	Phase 3	Lenalidomide;Chlorambucil
45	Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL)	Completed	NCT00564512	Phase 3	cyclophosphamide;fludarabine
46	Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia	Completed	NCT00003764	Phase 3	cyclophosphamide;fludarabine phosphate
47	Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia	Completed	NCT00262795	Phase 3	Fludarabine;Chlorambucil
48	Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity	Completed	NCT00281892	Phase 3	Fludarabine mono
49	Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia	Completed	NCT00262782	Phase 3	Fludarabine
50	A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia	Completed	NCT00254163	Phase 3	Fludarabine;Cyclophosphamide;Rituximab;Pentostatin

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

alemtuzumab

Chlorambucil

Cladribine

Cyclophosphamide

etoposide phosphate

fludarabine

Fludarabine phosphate

Ibrutinib

Ifosfamide

Immunoglobulins, Intravenous

mercaptopurine

pegaspargase

Uracil Mustard

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Leukemia, Chronic Lymphocytic cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Leukemia, Chronic Lymphocytic:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies
	StemEx, umbilical cord blood stem/progenitor cells for hematological diseases

Embryonic/Adult Cultured Cells Related to Leukemia, Chronic Lymphocytic:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells
	Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Cochrane evidence based reviews: leukemia, lymphocytic, chronic, b-cell

Sources

Genetic Tests for Leukemia, Chronic Lymphocytic

Genetic tests related to Leukemia, Chronic Lymphocytic:

#	Genetic test	Affiliating Genes
1	B-Cell Chronic Lymphocytic Leukemia ²⁸

Sources

Anatomical Context for Leukemia, Chronic Lymphocytic

Organs/tissues related to Leukemia, Chronic Lymphocytic:

MalaCards : Bone Marrow, Bone, T Cells, Lymph Node, B Cells, Spleen, Liver

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Chronic Lymphocytic:

#	Tissue Anatomical CompartmentCell	Relevance
1	Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells	Potential therapeutic candidate
2	Blood Peripheral Blood Mature B-Cells	Affected by disease
3	Blood Hematopoietic Bone Marrow Small Pre B-Cells	Affected by disease

Sources

Publications for Leukemia, Chronic Lymphocytic

Articles related to Leukemia, Chronic Lymphocytic:

(show top 50) (show all 24922)

#	Title	Authors	PMID	Year
1	A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. ⁶² ⁴⁶ ⁵⁷	Calin GA...Croce CM	16251535	2005
2	miR-15 and miR-16 induce apoptosis by targeting BCL2. ⁶² ⁴⁶ ⁵⁷	Cimmino A...Croce CM	16166262	2005
3	ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. ⁵³ ⁶² ⁵⁷	Wiestner A...Staudt LM	12595313	2003
4	ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. ⁵³ ⁶² ⁵⁷	Crespo M...Montserrat E	12724482	2003
5	Non-coding recurrent mutations in chronic lymphocytic leukaemia. ⁶² ⁵⁷	Puente XS...Campo E	26200345	2015
6	Mutations driving CLL and their evolution in progression and relapse. ⁶² ⁵⁷	Landau DA...Wu CJ	26466571	2015
7	Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. ⁶² ⁵	Woyach JA...Byrd JC	24869598	2014
8	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. ⁶² ⁵⁷	Berndt SI...Slager SL	23770605	2013
9	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. ⁶² ⁵⁷	Quesada V...Lopez-Otin C	22158541	2011
10	SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. ⁶² ⁵⁷	Wang L...Wu CJ	22150006	2011
11	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. ⁶² ⁵⁷	Puente XS...Campo E	21642962	2011
12	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. ⁶² ⁵⁷	Slager SL...Cerhan JR	21131588	2011
13	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. ⁵³ ⁶² ⁴⁶	Visone R...Croce CM	19717645	2009
14	Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. ⁶² ⁵⁷	Ng D...Toro JR	17047154	2007
15	Trinucleotide repeat dynamic mutation identifying susceptibility in familial and sporadic chronic lymphocytic leukaemia. ⁶² ⁵⁷	Auer RL...Cotter FE	17116127	2007
16	HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. ⁶² ⁵⁷	Scielzo C...Caligaris-Cappio F	15931393	2005
17	Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. ⁶² ⁵⁷	Goldin LR...Hemminki K	15161669	2004
18	Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. ⁶² ⁵⁷	Calin GA...Croce CM	14973191	2004
19	Cytogenetic findings in familial B-cell chronic lymphocytic leukemia: a report of two cases in a family. ⁶² ⁵⁷	Espinet B...Sole F	12781453	2003
20	Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. ⁶² ⁵⁷	Calin GA...Croce CM	12434020	2002
21	Hereditary chronic lymphocytic leukemia: an extended family study and literature review. ⁶² ⁵⁷	Lynch HT...Sanger WG	12407690	2002
22	A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. ⁶² ⁵⁷	Wiley JS...Manoharan A	11943260	2002
23	Genomic aberrations and survival in chronic lymphocytic leukemia. ⁶² ⁵⁷	Dohner H...Lichter P	11136261	2000
24	Linkage analysis for major histocompatibility complex-related genetic susceptibility in familial chronic lymphocytic leukemia. ⁶² ⁵⁷	Bevan S...Houlston RS	11090088	2000
25	Anticipation in familial chronic lymphocytic leukemia. ⁶² ⁵⁷	Goldin LR...Caporaso N	10364544	1999
26	Anticipation in familial leukemia. ⁶² ⁵⁷	Horwitz M...Jarvik GP	8900225	1996
27	Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. ⁶² ⁵⁷	McKeithan TW...Diaz MO	3122218	1987
28	Human heavy-chain variable region gene family nonrandomly rearranged in familial chronic lymphocytic leukemia. ⁶² ⁵⁷	Shen A...Blattner F	3120193	1987
29	Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. ⁶² ⁵⁷	Tsujimoto Y...Croce CM	3923362	1985
30	Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. ⁶² ⁵⁷	Tsujimoto Y...Croce CM	6610211	1984
31	Familial chronic lymphocytic leukemia. ⁶² ⁵⁷	Neuland CY...Strong DM	6418939	1983
32	Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease. ⁶² ⁵⁷	Conley CL...Laster AJ	7001171	1980
33	Lymphocyte studies in familial chronic lymphatic leukemia. ⁶² ⁵⁷	Branda RF...Douglas SD	637060	1978
34	Familial chronic lymphocytic leukemia. Immunologic and cellular characterization. ⁶² ⁵⁷	Blattner WA...Fraumeni JF	818930	1976
35	Familial chronic lymphocytic leukemia. ⁶² ⁵⁷	Fraumeni JF...DeVita VT	4184386	1969
36	An abnormal chromosome in chronic lymphocytic leukaemia. ⁶² ⁵⁷	GUNZ FW...ADAMS A	13951305	1962
37	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
38	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
39	Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. ⁶² ⁴⁶	Zhu DX...Li JY	21130495	2011
40	Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. ⁶² ⁴⁶	Santanam U...Pekarsky Y	20566844	2010
41	microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. ⁶² ⁴⁶	Asslaber D...Greil R	20089965	2010
42	miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. ⁶² ⁴⁶	Pallasch CP...Wendtner CM	19692702	2009
43	microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. ⁶² ⁴⁶	Stamatopoulos B...Lagneaux L	19144983	2009
44	Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. ⁶² ⁴⁶	Sampath D...Plunkett W	19096009	2009
45	17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. ⁶² ⁴⁶	Dijkstra MK...Jongen-Lavrencic M	18818704	2009
46	MiR-15a and miR-16-1 cluster functions in human leukemia. ⁶² ⁴⁶	Calin GA...Croce CM	18362358	2008
47	Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. ⁶² ⁴⁶	Marton S...Cayota A	17989717	2008
48	Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. ⁵	Estep AL...Rauen KA	18060073	2007
49	The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. ⁶² ⁴⁶	Calin GA...Croce CM	17707831	2007
50	Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. ⁶² ⁴⁶	Fulci V...Macino G	17327404	2007

Sources

Genes for Leukemia, Chronic Lymphocytic

Genes related to Leukemia, Chronic Lymphocytic (25 elite genes):

(show top 50) (show all 338)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TP53	Tumor Protein P53	Protein Coding	783.26	Pathogenic ⁵ Causative somatic mutation ⁵⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴	21435757 17920683 16737921 (more) 16938579 21205967 26619011
2	MIR15A	MicroRNA 15a	RNA Gene	412.81	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	15284443 16251535
3	MIR16-1	MicroRNA 16-1	RNA Gene	410.16	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	15284443 16251535
4	MIR34A	MicroRNA 34a	RNA Gene	406.59	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴	20089965 18818704
5	MIR181A2	MicroRNA 181a-2	RNA Gene	400	Causal ⁴⁶ Unspecified ⁴⁶	19692702 19717645 17989717
6	CCND1	Cyclin D1	Protein Coding	374.45	Gene fusion ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16393687 10781679 1290353 (more) 9436924 8573535 15608391 9548443 8548734 9376597 7919385 11863220 10319380 9556424 11697516 9652725 10478136 7545645 12591969
7	ATM	ATM Serine/Threonine Kinase	Protein Coding	364.89	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10397742 19018867 19035176 (more) 18928637 16053658 19898425 18035414 10319386 10699895
8	MIR29A	MicroRNA 29a	RNA Gene	359.04	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	20566844
9	MIR424	MicroRNA 424	RNA Gene	358.08	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	19692702
10	MIR145	MicroRNA 145	RNA Gene	356.13	Causal ⁴⁶ DISEASES inferred ¹⁴	17892514
11	MIR143	MicroRNA 143	RNA Gene	355.96	Causal ⁴⁶ DISEASES inferred ¹⁴	17892514
12	IKZF3	IKAROS Family Zinc Finger 3	Protein Coding	355.95	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴	26466571
13	RPS15	Ribosomal Protein S15	Protein Coding	355.94	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴	26466571 26675346
14	MIR106B	MicroRNA 106b	RNA Gene	355.53	Causal ⁴⁶ DISEASES inferred ¹⁴	19096009
15	POT1	Protection Of Telomeres 1	Protein Coding	355.51	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴	23502782
16	MIR107	MicroRNA 107	RNA Gene	355.04	Causal ⁴⁶ DISEASES inferred ¹⁴	19692702
17	IGHG1	Immunoglobulin Heavy Constant Gamma 1 (G1m Marker)	Protein Coding	350	Gene fusion ⁵⁸
18	CLLS1	Leukemia, Chronic Lymphocytic, Susceptibility To, 1	Genetic Locus	58.61	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
19	CLLS3	Leukemia, Chronic Lymphocytic, Susceptibility To, 3	Genetic Locus	58.61	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
20	CLLS4	Leukemia, Chronic Lymphocytic Susceptibility To, 4	Genetic Locus	58.61	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
21	CLLS5	Leukemia, Chronic Lymphocytic Susceptiblity To, 5	Genetic Locus	58.61	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
22	CLLS2	Disrupted In B-Cell Neoplasia	Genetic Locus	50	MalaCards inferred ³⁹
23	ARL11	ADP Ribosylation Factor Like GTPase 11	Protein Coding	37.64	Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	15843669
24	P2RX7	Purinergic Receptor P2X 7	Protein Coding	35.94	Orphanet ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12493261 18937793 15184265
25	IGHV3-21	Immunoglobulin Heavy Variable 3-21	Protein Coding	25	Orphanet ⁵⁸	22464020 23637131 22875913 (more) 21372840
26	DLEU1	Deleted In Lymphocytic Leukemia 1	RNA Gene	156.06	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	9395242 11161783 19347735
27	TP53COR1	Tumor Protein P53 Pathway Corepressor 1	RNA Gene	154.98	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24583225 25971364
28	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	154.58	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25971364
29	CRNDE	Colorectal Neoplasia Differentially Expressed	RNA Gene	154.57	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	27777635
30	MIAT	Myocardial Infarction Associated Transcript	RNA Gene	154.55	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27527866
31	MIR155HG	MIR155 Host Gene	RNA Gene	154.4	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	21296997
32	DLEU2	Deleted In Lymphocytic Leukemia 2	RNA Gene	154.26	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	9395242 11072235 11161783 (more) 19347735 19591824
33	TRERNA1	Translation Regulatory Long Non-Coding RNA 1	RNA Gene	153.58	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28412730
34	GATA6-AS1	GATA6 Antisense RNA 1 (Head To Head)	RNA Gene	150	Experimental evidence: Locus ³⁷	27689399
35	MIR155	MicroRNA 155	RNA Gene	61.52	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	17327404
36	MIR181A1	MicroRNA 181a-1	RNA Gene	60.34	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	15284443
37	MIR21	MicroRNA 21	RNA Gene	60.15	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	17327404
38	MIR15B	MicroRNA 15b	RNA Gene	59.78	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	15284443
39	MIR92A1	MicroRNA 92a-1	RNA Gene	59.51	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	15284443
40	MIR150	MicroRNA 150	RNA Gene	59.33	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	17327404
41	MIR24-1	MicroRNA 24-1	RNA Gene	59.17	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	16251535
42	MIR29C	MicroRNA 29c	RNA Gene	59.13	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	16251535
43	MIR140	MicroRNA 140	RNA Gene	58.3	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	15284443
44	MIR141	MicroRNA 141	RNA Gene	58.27	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	15284443
45	MIR154	MicroRNA 154	RNA Gene	56.7	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	15284443
46	MIR221	MicroRNA 221	RNA Gene	56.14	Unspecified ⁴⁶ DISEASES inferred ¹⁴	16251535
47	MIR223	MicroRNA 223	RNA Gene	56.07	Unspecified ⁴⁶ DISEASES inferred ¹⁴	16251535
48	MIR146A	MicroRNA 146a	RNA Gene	55.99	Unspecified ⁴⁶ DISEASES inferred ¹⁴	16251535
49	MIR19A	MicroRNA 19a	RNA Gene	55.84	Unspecified ⁴⁶ DISEASES inferred ¹⁴	15284443
50	MIR10B	MicroRNA 10b	RNA Gene	55.81	Unspecified ⁴⁶ DISEASES inferred ¹⁴	15284443

Sources

Variations for Leukemia, Chronic Lymphocytic

ClinVar genetic disease variations for Leukemia, Chronic Lymphocytic:

⁵ (show top 50) (show all 106)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TP53	NM_000546.6(TP53):c.-19_*21del (p.Met1fs)	DEL	Pathogenic	1174011		GRCh37: 17:7572906-7579931 GRCh38: 17:7669588-7676613
2	TP53	NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)	SNV	Pathogenic	127819	rs121912666	GRCh37: 17:7578190-7578190 GRCh38: 17:7674872-7674872
3	TP53	NM_000546.6(TP53):c.743G>T (p.Arg248Leu)	SNV	Likely Pathogenic	230253	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
4	TP53	NM_000546.6(TP53):c.818G>A (p.Arg273His)	SNV	Likely Pathogenic	12366	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
5	TP53	NM_000546.6(TP53):c.817C>A (p.Arg273Ser)	SNV	Likely Pathogenic	376656	rs121913343	GRCh37: 17:7577121-7577121 GRCh38: 17:7673803-7673803
6	TP53	NM_000546.6(TP53):c.841G>T (p.Asp281Tyr)	SNV	Likely Pathogenic	376585	rs764146326	GRCh37: 17:7577097-7577097 GRCh38: 17:7673779-7673779
7	BRAF	NM_004333.6(BRAF):c.1803A>C (p.Lys601Asn)	SNV	Likely Pathogenic	376286	rs121913365	GRCh37: 7:140453132-140453132 GRCh38: 7:140753332-140753332
8	SF3B1	NM_012433.4(SF3B1):c.2225G>A (p.Gly742Asp)	SNV	Likely Pathogenic	376530	rs755415626	GRCh37: 2:198266611-198266611 GRCh38: 2:197401887-197401887
9	PLCG2	NM_002661.5(PLCG2):c.2535A>C (p.Leu845Phe)	SNV	Likely Pathogenic	376214	rs1057519832	GRCh37: 16:81962183-81962183 GRCh38: 16:81928578-81928578
10	SF3B1	NM_012433.4(SF3B1):c.1874G>A (p.Arg625His)	SNV	Likely Pathogenic	376534	rs1057519961	GRCh37: 2:198267483-198267483 GRCh38: 2:197402759-197402759
11	SF3B2	NM_006842.3(SF3B2):c.1997A>C (p.His666Pro)	SNV	Likely Pathogenic	376531	rs1057519959	GRCh37: 11:65830499-65830499 GRCh38: 11:66063028-66063028
12	PTPN11	NM_002834.5(PTPN11):c.215C>A (p.Ala72Asp)	SNV	Likely Pathogenic	376511	rs121918454	GRCh37: 12:112888199-112888199 GRCh38: 12:112450395-112450395
13	SF3B1	NM_012433.4(SF3B1):c.1873C>T (p.Arg625Cys)	SNV	Likely Pathogenic	376535	rs775623976	GRCh37: 2:198267484-198267484 GRCh38: 2:197402760-197402760
14	SF3B1	NM_012433.4(SF3B1):c.1996A>G (p.Lys666Glu)	SNV	Likely Pathogenic	376008	rs754688962	GRCh37: 2:198267361-198267361 GRCh38: 2:197402637-197402637
15	MYD88	NM_002468.5(MYD88):c.755T>C (p.Leu252Pro)	SNV	Likely Pathogenic	37055	rs387907272	GRCh37: 3:38182641-38182641 GRCh38: 3:38141150-38141150
16	XPO1	NM_003400.4(XPO1):c.1712A>T (p.Glu571Val)	SNV	Likely Pathogenic	376696	rs1057520010	GRCh37: 2:61719471-61719471 GRCh38: 2:61492336-61492336
17	XPO1	NM_003400.4(XPO1):c.1712A>C (p.Glu571Ala)	SNV	Likely Pathogenic	376697	rs1057520010	GRCh37: 2:61719471-61719471 GRCh38: 2:61492336-61492336
18	PLCG2	NM_002661.5(PLCG2):c.2535A>T (p.Leu845Phe)	SNV	Likely Pathogenic	376215	rs1057519832	GRCh37: 16:81962183-81962183 GRCh38: 16:81928578-81928578
19	SF3B1	NM_012433.4(SF3B1):c.1873C>G (p.Arg625Gly)	SNV	Likely Pathogenic	376536	rs775623976	GRCh37: 2:198267484-198267484 GRCh38: 2:197402760-197402760
20	PLCG2	NM_002661.5(PLCG2):c.1993C>T (p.Arg665Trp)	SNV	Likely Pathogenic	376213	rs1057519831	GRCh37: 16:81946260-81946260 GRCh38: 16:81912655-81912655
21	XPO1	NM_003400.4(XPO1):c.1711G>A (p.Glu571Lys)	SNV	Likely Pathogenic	376695	rs1057520009	GRCh37: 2:61719472-61719472 GRCh38: 2:61492337-61492337
22	SF3B1	NM_012433.4(SF3B1):c.1996A>C (p.Lys666Gln)	SNV	Likely Pathogenic	376532	rs754688962	GRCh37: 2:198267361-198267361 GRCh38: 2:197402637-197402637
23	NRAS	NM_002524.5(NRAS):c.181C>A (p.Gln61Lys)	SNV	Likely Pathogenic	73058	rs121913254	GRCh37: 1:115256530-115256530 GRCh38: 1:114713909-114713909
24	TP53	NM_000546.6(TP53):c.641A>T (p.His214Leu)	SNV	Likely Pathogenic	376616	rs1057519992	GRCh37: 17:7578208-7578208 GRCh38: 17:7674890-7674890
25	NRAS	NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)	SNV	Likely Pathogenic	13900	rs11554290	GRCh37: 1:115256529-115256529 GRCh38: 1:114713908-114713908
26	HRAS, LRRC56	NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)	SNV	Likely Pathogenic	12606	rs104894228	GRCh37: 11:534286-534286 GRCh38: 11:534286-534286
27	BRAF	NM_004333.6(BRAF):c.1801A>G (p.Lys601Glu)	SNV	Likely Pathogenic	13966	rs121913364	GRCh37: 7:140453134-140453134 GRCh38: 7:140753334-140753334
28	TP53	NM_000546.6(TP53):c.842A>T (p.Asp281Val)	SNV	Likely Pathogenic	182968	rs587781525	GRCh37: 17:7577096-7577096 GRCh38: 17:7673778-7673778
29	TP53	NM_000546.6(TP53):c.578A>G (p.His193Arg)	SNV	Likely Pathogenic	184979	rs786201838	GRCh37: 17:7578271-7578271 GRCh38: 17:7674953-7674953
30	TP53	NM_000546.6(TP53):c.724T>A (p.Cys242Ser)	SNV	Likely Pathogenic	376579	rs1057519982	GRCh37: 17:7577557-7577557 GRCh38: 17:7674239-7674239
31	TP53	NM_000546.6(TP53):c.578A>T (p.His193Leu)	SNV	Likely Pathogenic	185822	rs786201838	GRCh37: 17:7578271-7578271 GRCh38: 17:7674953-7674953
32	TP53	NM_000546.6(TP53):c.712T>C (p.Cys238Arg)	SNV	Likely Pathogenic	376576	rs1057519981	GRCh37: 17:7577569-7577569 GRCh38: 17:7674251-7674251
33	TP53	NM_000546.6(TP53):c.764T>A (p.Ile255Asn)	SNV	Likely Pathogenic	232289	rs876659675	GRCh37: 17:7577517-7577517 GRCh38: 17:7674199-7674199
34	TP53	NM_000546.6(TP53):c.818G>T (p.Arg273Leu)	SNV	Likely Pathogenic	376655	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
35	TP53	NM_000546.6(TP53):c.742C>T (p.Arg248Trp)	SNV	Likely Pathogenic	12347	rs121912651	GRCh37: 17:7577539-7577539 GRCh38: 17:7674221-7674221
36	TP53	NM_000546.6(TP53):c.841G>A (p.Asp281Asn)	SNV	Likely Pathogenic	376586	rs764146326	GRCh37: 17:7577097-7577097 GRCh38: 17:7673779-7673779
37	TP53	NM_000546.6(TP53):c.577C>T (p.His193Tyr)	SNV	Likely Pathogenic	230256	rs876658468	GRCh37: 17:7578272-7578272 GRCh38: 17:7674954-7674954
38	TP53	NM_000546.6(TP53):c.742C>G (p.Arg248Gly)	SNV	Likely Pathogenic	376652	rs121912651	GRCh37: 17:7577539-7577539 GRCh38: 17:7674221-7674221
39	TP53	NM_000546.6(TP53):c.713G>C (p.Cys238Ser)	SNV	Likely Pathogenic	376575	rs730882005	GRCh37: 17:7577568-7577568 GRCh38: 17:7674250-7674250
40	TP53	NM_000546.6(TP53):c.584T>A (p.Ile195Asn)	SNV	Likely Pathogenic	376618	rs760043106	GRCh37: 17:7578265-7578265 GRCh38: 17:7674947-7674947
41	TP53	NM_000546.6(TP53):c.725G>A (p.Cys242Tyr)	SNV	Likely Pathogenic	12354	rs121912655	GRCh37: 17:7577556-7577556 GRCh38: 17:7674238-7674238
42	TP53	NM_000546.6(TP53):c.841G>C (p.Asp281His)	SNV	Likely Pathogenic	376588	rs764146326	GRCh37: 17:7577097-7577097 GRCh38: 17:7673779-7673779
43	TP53	NM_000546.6(TP53):c.584T>C (p.Ile195Thr)	SNV	Likely Pathogenic	216077	rs760043106	GRCh37: 17:7578265-7578265 GRCh38: 17:7674947-7674947
44	TP53	NM_000546.6(TP53):c.713G>A (p.Cys238Tyr)	SNV	Likely Pathogenic	182935	rs730882005	GRCh37: 17:7577568-7577568 GRCh38: 17:7674250-7674250
45	TP53	NM_000546.6(TP53):c.523C>T (p.Arg175Cys)	SNV	Likely Pathogenic	245851	rs138729528	GRCh37: 17:7578407-7578407 GRCh38: 17:7675089-7675089
46	TP53	NM_000546.6(TP53):c.843C>G (p.Asp281Glu)	SNV	Likely Pathogenic	376587	rs1057519984	GRCh37: 17:7577095-7577095 GRCh38: 17:7673777-7673777
47	TP53	NM_000546.6(TP53):c.712T>G (p.Cys238Gly)	SNV	Likely Pathogenic	376577	rs1057519981	GRCh37: 17:7577569-7577569 GRCh38: 17:7674251-7674251
48	PTPN11	NM_002834.5(PTPN11):c.215C>T (p.Ala72Val)	SNV	Likely Pathogenic	41443	rs121918454	GRCh37: 12:112888199-112888199 GRCh38: 12:112450395-112450395
49	TP53	NM_000546.6(TP53):c.725G>T (p.Cys242Phe)	SNV	Likely Pathogenic	376578	rs121912655	GRCh37: 17:7577556-7577556 GRCh38: 17:7674238-7674238
50	TP53	NM_000546.6(TP53):c.824G>C (p.Cys275Ser)	SNV	Likely Pathogenic	376583	rs863224451	GRCh37: 17:7577114-7577114 GRCh38: 17:7673796-7673796

Copy number variations for Leukemia, Chronic Lymphocytic from CNVD:

⁶ (show top 50) (show all 1219)

#	CNVD ID	Chromosome	Start	End	Type	CNVD Disease
1	14042	1	103366560	104230405	Loss	Chronic lymphocytic leukemia
2	14895	1	110954839	111582296	Loss	Chronic lymphocytic leukemia
3	14947	1	111421057	111642223	Loss	Chronic lymphocytic leukemia
4	15456	1	115719205	117399077	Loss	Chronic lymphocytic leukemia
5	17206	1	141510591	145121245	Deletion	Chronic lymphocytic leukemia
6	17207	1	141510591	145121245	Loss	Chronic lymphocytic leukemia
7	18527	1	146265358	148164994	Gain	Chronic lymphocytic leukemia
8	19758	1	151208615	155645185	Gain	Chronic lymphocytic leukemia
9	20025	1	152611898	157344161	Loss	Chronic lymphocytic leukemia
10	21378	1	158336749	159355008	Loss	Chronic lymphocytic leukemia
11	21384	1	158391645	159433573	Loss	Chronic lymphocytic leukemia
12	21385	1	158391645	189498990	Loss	Chronic lymphocytic leukemia
13	23023	1	170758115	170759115	Loss	Chronic lymphocytic leukemia
14	23030	1	170822660	170823660	Gain	Chronic lymphocytic leukemia
15	23626	1	172107770	172108770	Gain	Chronic lymphocytic leukemia
16	24171	1	176708253	177307399	Gain	Chronic lymphocytic leukemia
17	25274	1	186459864	186720923	Loss	Chronic lymphocytic leukemia
18	25359	1	187890295	188217703	Loss	Chronic lymphocytic leukemia
19	25435	1	189143434	189363313	Gain	Chronic lymphocytic leukemia
20	25473	1	189804292	192389810	Gain	Chronic lymphocytic leukemia
21	25685	1	193314169	193528753	Gain	Chronic lymphocytic leukemia
22	26789	1	202768030	203457313	Loss	Chronic lymphocytic leukemia
23	26818	1	203067017	205298659	Loss	Chronic lymphocytic leukemia
24	26975	1	204424298	206588789	Loss	Chronic lymphocytic leukemia
25	28076	1	218313329	220732423	Loss	Chronic lymphocytic leukemia
26	28130	1	218942571	219164038	Loss	Chronic lymphocytic leukemia
27	28133	1	218959043	244561923	Loss	Chronic lymphocytic leukemia
28	28265	1	220678511	222112407	Gain	Chronic lymphocytic leukemia
29	28321	1	221304071	221582122	Gain	Chronic lymphocytic leukemia
30	28577	1	223594083	225234079	Loss	Chronic lymphocytic leukemia
31	28643	1	224353010	225571533	Loss	Chronic lymphocytic leukemia
32	28702	1	224857883	233411748	Loss	Chronic lymphocytic leukemia
33	29066	1	227299711	227518155	Loss	Chronic lymphocytic leukemia
34	29113	1	227696842	233631743	Loss	Chronic lymphocytic leukemia
35	29265	1	229664393	229947546	Gain	Chronic lymphocytic leukemia
36	29501	1	232707626	233302391	Loss	Chronic lymphocytic leukemia
37	31053	1	24943712	26054939	Loss	Chronic lymphocytic leukemia
38	31193	1	25985121	29490451	Deletion	Chronic lymphocytic leukemia
39	31425	1	27504484	28494376	Loss	Chronic lymphocytic leukemia
40	32443	1	36783544	38823237	Loss	Chronic lymphocytic leukemia
41	33495	1	45606989	46307302	Gain	Chronic lymphocytic leukemia
42	34016	1	51545765	53346467	Loss	Chronic lymphocytic leukemia
43	34255	1	54029769	55100800	Loss	Chronic lymphocytic leukemia
44	34911	1	57712092	58034742	Gain	Chronic lymphocytic leukemia
45	35379	1	62697088	63142732	Loss	Chronic lymphocytic leukemia
46	35406	1	63335974	63596958	Gain	Chronic lymphocytic leukemia
47	35407	1	63335974	63641668	Gain	Chronic lymphocytic leukemia
48	36497	1	76364563	76710672	Loss	Chronic lymphocytic leukemia
49	36890	1	82341866	82576806	Loss	Chronic lymphocytic leukemia
50	36895	1	82581235	82812961	Loss	Chronic lymphocytic leukemia

Sources

Expression for Leukemia, Chronic Lymphocytic

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic.

Sources

Pathways for Leukemia, Chronic Lymphocytic

Pathways related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

(show all 12)

#	Super pathways	Score	Top Affiliating Genes
1	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	11.71	TP53 MIR15A MIR145 CCND1 ATM
2	DNA damage response (only ATM dependent) ⁷⁴	11.68	TP53 CCND1 ATM
3	Regulation of Telomerase ⁶¹	11.49	POT1 CCND1 ATM
4	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.46	MIR143 MIR145 MIR16-1 MIR181A2
5	miRNAs involvement in the immune response in sepsis ⁷⁴	11.43	MIR16-1 MIR145 MIR106B
6	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.32	TP53 MIR34A CCND1
7	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.19	TP53 CCND1 ATM
8	miRNAs involved in DNA damage response ⁷⁴	11.15	TP53 MIR424 MIR29A MIR16-1 MIR15A MIR145
9	GADD45 Pathway ⁶⁴	11	TP53 CCND1 ATM
10	DNA Damage Induced 14-3-3Sigma Signaling ⁶⁴	10.79	TP53 ATM
11	PLK3 signaling events ⁶¹	10.21	TP53 ATM
12	MicroRNA network associated with chronic lymphocytic leukemia ⁷⁴	9.91	TP53 MIR16-1 MIR15A

Sources

GO Terms for Leukemia, Chronic Lymphocytic

Cellular components related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.62	NEAT1 MIR424 MIR29A MIR181A2 MIR16-1 MIR15A
2	extracellular vesicle	GO:1903561	9.43	MIR34A MIR29A MIR16-1 MIR15A MIR107 MIR106B

Biological processes related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

(show all 25)

#	Name	GO ID	Score	Top Affiliating Genes
1	miRNA-mediated gene silencing	GO:0035195	10.2	MIR106B MIR107 MIR143 MIR145 MIR15A MIR16-1
2	positive regulation of apoptotic process	GO:0043065	10.15	TP53 MIR29A MIR16-1 MIR15A ATM
3	negative regulation of gene expression	GO:0010629	9.99	TP53 MIR34A MIR29A MIR181A2 MIR106B
4	regulation of telomere maintenance via telomerase	GO:0032210	9.88	POT1 ATM
5	negative regulation of inflammatory response	GO:0050728	9.86	MIR181A2 MIR16-1 MIR15A MIR145
6	positive regulation of intrinsic apoptotic signaling pathway	GO:2001244	9.84	TP53 MIR16-1 MIR15A
7	negative regulation of protein kinase B signaling	GO:0051898	9.79	MIR34A MIR29A MIR145
8	negative regulation of G1/S transition of mitotic cell cycle	GO:2000134	9.77	MIR29A MIR16-1 MIR15A
9	positive regulation of cardiac muscle cell apoptotic process	GO:0010666	9.76	MIR16-1 MIR34A TP53
10	negative regulation of vascular associated smooth muscle cell proliferation	GO:1904706	9.72	MIR424 MIR34A MIR15A
11	negative regulation of cell migration involved in sprouting angiogenesis	GO:0090051	9.7	MIR424 MIR16-1 MIR15A
12	negative regulation of vascular associated smooth muscle cell migration	GO:1904753	9.65	MIR424 MIR34A MIR15A
13	angiotensin-activated signaling pathway	GO:0038166	9.62	MIR145 MIR143
14	positive regulation of connective tissue replacement	GO:1905205	9.61	MIR34A MIR16-1
15	negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis	GO:1903588	9.61	MIR15A MIR16-1 MIR424
16	aorta smooth muscle tissue morphogenesis	GO:0060414	9.58	MIR143 MIR145
17	negative regulation of amyloid precursor protein catabolic process	GO:1902992	9.57	MIR107 MIR29A
18	negative regulation of vascular endothelial growth factor production	GO:1904046	9.56	MIR34A MIR16-1 MIR15A MIR107
19	negative regulation of angiogenesis	GO:0016525	9.56	MIR424 MIR34A MIR29A MIR16-1 MIR15A MIR145
20	negative regulation of endothelial cell chemotaxis to fibroblast growth factor	GO:2000545	9.51	MIR424 MIR16-1
21	regulation of phenotypic switching	GO:1900239	9.49	MIR145 MIR143
22	negative regulation of endothelial cell chemotaxis to vascular endothelial growth factor	GO:1904858	9.4	MIR424 MIR16-1
23	negative regulation of cell chemotaxis to fibroblast growth factor	GO:1904848	9.37	MIR16-1 MIR15A
24	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	9.32	MIR145 MIR143
25	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.17	MIR29A MIR181A2 MIR16-1 MIR15A MIR145 MIR107

Molecular functions related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.7	TP53 MIR424 MIR34A MIR29A MIR181A2 MIR16-1
2	mRNA base-pairing translational repressor activity	GO:1903231	9.32	MIR424 MIR34A MIR29A MIR181A2 MIR16-1 MIR15A